MedTrace Logo

The Randomized OPTIMAL-ACT Trial

NCT03772613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes

Conditions

Interventions

DRUG

Unfractionated heparin

Administration of unfractionated heparin will be assessed using the activated clotting time

Sponsors & Collaborators

Principal Investigators

  • Shahyar M Gharacholou, MD, MSc · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-08
Primary Completion
2021-10-25
Completion
2021-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772613 on ClinicalTrials.gov